Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Immunomedics is drawing a deeper line under its woes with a new head of research from AstraZeneca.
Menlo says it will proceed as planned with two phase 3 trials of serlopitant in prurigo nodularis later this quarter, eyeing an NDA in 2020.
After a tough few months, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with ties to the company.
The combination of Incyte’s epacadostat and Merck & Co.’s Keytruda was supposed to pose a major threat to Bristol-Myers Squibb’s melanoma franchise.
Hitting the IPO target would bring the preclinical anti-aging startup’s fundraising haul up toward $300 million.
Conatus Pharma’s lead drug emricasan missed the mark in its first midstage clinical test, driving down its stock.
Amgen joined with MP Healthcare Venture Management and Alexandria Venture Investments to put the latest tranche of funding into QurAlis.
The latest setback marks the end of the line for Luigi Costa, who is stepping down as CEO by “mutual agreement” with the company’s board.
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.